StockNews.com Begins Coverage on Acorda Therapeutics (NASDAQ:ACOR)

StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a report issued on Saturday morning. The firm issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

NASDAQ:ACOR opened at $0.66 on Friday. The company has a fifty day moving average of $11.13 and a 200-day moving average of $12.16. The firm has a market capitalization of $819,640.00, a P/E ratio of 0.00 and a beta of 1.40. The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07. Acorda Therapeutics has a twelve month low of $0.61 and a twelve month high of $24.20.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.